Search research articles
Contact Us
Filters
Showing results (171-180 of 211) with videos related to
Page
of 22
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
August 4, 2025
Digital Versus Manual PD-L1 Scoring in Advanced NSCLC From the IMpower110 and IMpower150 Trials
Roy S Herbst, Hen Prizant, Daniel Ruderman, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
November 6, 2014
PRONOUNCE: randomized, open-label, phase III study of first-line pemetrexed + carboplatin followed by maintenance pemetrexed versus paclitaxel + carboplatin + bevacizumab followed by maintenance bevacizumab in patients ith advanced nonsquamous non-small-cell lung cancer
Ralph G Zinner, Coleman K Obasaju, David R Spigel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 10, 2020
Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: CheckMate 153
David M Waterhouse, Edward B Garon, Jason Chandler, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
April 30, 2026
Long-Term Impact of First-Line Amivantamab Plus Lazertinib Versus Osimertinib on Mechanisms of Acquired Resistance in MARIPOSA: A Brief Report
Hidetoshi Hayashi, Byoung Chul Cho, David R Spigel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 6, 2024
A Phase Ib/II Randomized Clinical Trial of Oleclumab with or without Durvalumab plus Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
Andrew L Coveler, Matthew J Reilley, Mark Zalupski, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 29, 2020
Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update
Nasser H Hanna, Bryan J Schneider, Sarah Temin, et al.
The Lancet. Oncology
|
December 10, 2016
Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study
Charles M Rudin, M Catherine Pietanza, Todd M Bauer, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
January 21, 2021
Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC-an Update From the PACIFIC Trial
Corinne Faivre-Finn, David Vicente, Takayasu Kurata, et al.
JAMA Oncology
|
July 26, 2019
Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non-Small Cell Lung Cancer Treated With Nivolumab
Suzanne L Topalian, F Stephen Hodi, Julie R Brahmer, et al.
The New England Journal of Medicine
|
September 13, 2024
Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer
Ying Cheng, David R Spigel, Byoung Chul Cho, et al.
Page
of 22
Search research articles
Search
Showing results (171-180 of 211) with videos related to
Sort By:
Page
of 22
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
August 4, 2025
Digital Versus Manual PD-L1 Scoring in Advanced NSCLC From the IMpower110 and IMpower150 Trials
Roy S Herbst, Hen Prizant, Daniel Ruderman, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
November 6, 2014
PRONOUNCE: randomized, open-label, phase III study of first-line pemetrexed + carboplatin followed by maintenance pemetrexed versus paclitaxel + carboplatin + bevacizumab followed by maintenance bevacizumab in patients ith advanced nonsquamous non-small-cell lung cancer
Ralph G Zinner, Coleman K Obasaju, David R Spigel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 10, 2020
Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: CheckMate 153
David M Waterhouse, Edward B Garon, Jason Chandler, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
April 30, 2026
Long-Term Impact of First-Line Amivantamab Plus Lazertinib Versus Osimertinib on Mechanisms of Acquired Resistance in MARIPOSA: A Brief Report
Hidetoshi Hayashi, Byoung Chul Cho, David R Spigel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 6, 2024
A Phase Ib/II Randomized Clinical Trial of Oleclumab with or without Durvalumab plus Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
Andrew L Coveler, Matthew J Reilley, Mark Zalupski, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 29, 2020
Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update
Nasser H Hanna, Bryan J Schneider, Sarah Temin, et al.
The Lancet. Oncology
|
December 10, 2016
Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study
Charles M Rudin, M Catherine Pietanza, Todd M Bauer, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
January 21, 2021
Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC-an Update From the PACIFIC Trial
Corinne Faivre-Finn, David Vicente, Takayasu Kurata, et al.
JAMA Oncology
|
July 26, 2019
Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non-Small Cell Lung Cancer Treated With Nivolumab
Suzanne L Topalian, F Stephen Hodi, Julie R Brahmer, et al.
The New England Journal of Medicine
|
September 13, 2024
Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer
Ying Cheng, David R Spigel, Byoung Chul Cho, et al.
Page
of 22